uploads///Analysts Rating

Analysts’ Views on Alexion Pharmaceuticals and Its Peers


Jun. 1 2017, Updated 7:37 a.m. ET

Long-term growth drivers

Alexion Pharmaceuticals (ALXN) is focused on developing effective drugs for rare diseases. In March 2017, the company filed a supplemental Biologics License Application (sBLA) for Soliris as a therapy for refractory gMG (generalized myasthenia gravis). If the drug receives approval for this indication, Alexion Pharmaceuticals’ might witness higher revenue.

Currently, Alexion Pharmaceuticals is carrying out the PREVENT phase 3 trial, which is evaluating Soliris as s treatment option for relapsing Neuromyelitis Optica Spectrum Disorder.

Article continues below advertisement

Alexion Pharmaceuticals also expects promising results for ALXN1210, a long-acting anti-C5 antibody, which is being studied in phase 3 clinical trials for PHN (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic-uremic syndrome). The approval of Soliris for NMOSD and ALXN1210 for PNH and aHUS would boost the company’s long-term revenue growth.

Alexion Pharmaceuticals’ other products in clinical trials include cPMP for Molybdenum Cofactor Deficiency type A and SBC-103 for Mucopolysaccharidoses IIIB.

For Alexion Pharmaceuticals, increased product sales might fuel the share prices of the Vanguard Growth ETF (VUG). Alexion Pharmaceuticals holds ~0.21% of VUG’s total portfolio holdings.

Analysts’ recommendations

Of the 21 analysts analyzing Alexion Pharmaceuticals, six analysts recommended a “strong buy” and 11 analysts recommended a “buy.”

Four analysts recommended a “hold,” while ~80% of the analysts suggested some form of a “buy.”

Article continues below advertisement

Peers’ ratings

Out of 26 analysts analyzing Biogen (BIIB) in May 2017, seven analysts recommended a “strong buy,” while eight analysts recommended a “buy.” Ten analysts recommended a “hold,” while one analyst recommended a “sell.” Meanwhile, ~58% of the analysts covering Biogen suggested some form of a “buy.”

Out of 21 analysts analyzing BioMarin Pharmaceutical (BMRN) in May 2017, six analysts recommended a “strong buy,” while ten analysts recommended a “buy.” Five analysts recommended a “hold,” while none of the analysts recommended a “strong sell” or “sell.” Meanwhile, ~76% of the analysts suggested some form of a “buy.”

Of the six analysts analyzing Syros Pharmaceuticals (SYRS) in May 2017, two analysts recommended a “strong buy,” while three analysts recommended a “buy.” One analyst recommended a “hold.” No analysts recommended a “sell” or “strong sell.” Meanwhile, ~83% of the analysts recommended some form of a “buy.”


More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.